Clinical Trial Update: Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for a CALR-mutant peptide vaccine in myeloproliferative neoplasms; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Myeloproliferative Neoplasms

Drugs mentioned

• Mutant CALR-peptide Based Vaccine

Snippet

Sponsor: Marina Kremyanskaya | Conditions: Myelofibrosis, Essential Thrombocythemia | Phase 1 | Status: RECRUITING